Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.